Pasithea Therapeutics 株価情報 (NASDAQ: KTTA)

最新ニュース Pasithea Therapeutics (NASDAQ:KTTA) 株価情報

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

Century Aluminum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.56 by 35.71 percent. This is a 1300 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $633.90 million which beat the analyst consensus estimate of $577.60 million by 9.75 percent. This is a 29.50 percent increase over sales of $489.50 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

CENX

Century Aluminum Q1 Adj. EPS $0.36 Misses $0.56 Estimate, Sales $633.90M Beat $577.60M Estimate

Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.07 by 71.43 percent. This is a 140 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $155.77 million which beat the analyst consensus estimate of $144.20 million by 8.02 percent. This is a 4.32 percent increase over sales of $149.32 million the same period last year.

MGNI

Magnite Q1 Adj. EPS $0.12 Beats $0.07 Estimate, Sales $155.77M Beat $144.20M Estimate

WIIM

Zillow Group shares are trading lower after the company reported Q1 financial results and issued Q2 sales guidance with its midpoint below estimates.

Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) reported quarterly losses of $(1.91) per share which missed the analyst consensus estimate of $(0.50) by 282 percent. This is a 29.93 percent decrease over losses of $(1.47) per share from the same period last year. The company reported quarterly sales of $110.00 million which missed the analyst consensus estimate of $114.65 million by 4.06 percent. This is a 29.26 percent increase over sales of $85.10 million the same period last year.

HIPO

Hippo Holdings Q1 EPS $(1.91), Sales $110.00M Miss $114.65M Estimate

Guidance

IONQ

IonQ Sees Q2 Sales $16.000M-$18.000M vs $16.93M Est

IonQ Affirms FY2025 Sales Guidance of $75.00M-$95.00M vs $85.42M Est

Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) lowers FY2025 Adj EPS guidance from $0.07-$0.19 to $(0.07)-$0.03 vs $0.14 analyst estimate. Lowers FY2025 sales outlook from $66.00 million-$72.00 million to $64.00 million-$70.00 million vs $69.49 million estimate.

SVCO

Silvaco Group Lowers FY2025 Adj EPS Guidance from $0.07-$0.19 to $(0.07)-$0.03 vs $0.14 Est; Lowers FY2025 Sales Guidance from $66.00M-$72.00M to $64.00M-$70.00M vs $69.49M Est

Saratoga Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) reported quarterly earnings of $0.56 per share which missed the analyst consensus estimate of $0.70 by 20 percent. This is a 40.43 percent decrease over earnings of $0.94 per share from the same period last year. The company reported quarterly sales of $31.30 million which missed the analyst consensus estimate of $33.22 million by 5.79 percent. This is a 15.95 percent decrease over sales of $37.23 million the same period last year.

Saratoga Investment Q4 Adj. EPS $0.56 Misses $0.70 Estimate, Sales $31.30M Miss $33.22M Estimate

CVNA

Carvana shares are trading lower. The company reported Q1 financial results.

Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) reported quarterly losses of $(3.24) per share which missed the analyst consensus estimate of $(0.94) by 244.68 percent. This is a 62.11 percent increase over losses of $(8.55) per share from the same period last year. The company reported quarterly sales of $29.75 million which beat the analyst consensus estimate of $27.81 million by 6.98 percent. This is a 5.62 percent increase over sales of $28.17 million the same period last year.

Outset Medical Q1 Adj. EPS $(3.24) Misses $(0.94) Estimate, Sales $29.75M Beat $27.81M Estimate

AMC Enter Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.59) by 1.69 percent. This is a 25.64 percent increase over losses of $(0.78) per share from the same period last year. The company reported quarterly sales of $862.50 million which beat the analyst consensus estimate of $837.05 million by 3.04 percent. This is a 9.34 percent decrease over sales of $951.40 million the same period last year.

AMC Enter Hldgs Q1 Adj. EPS $(0.58) Beats $(0.59) Estimate, Sales $862.50M Beat $837.05M Estimate

APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.83 by 46.99 percent. This is a 43.59 percent decrease over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $1.38 billion which missed the analyst consensus estimate of $2.20 billion by 37.44 percent. This is a 27.69 percent decrease over sales of $1.90 billion the same period last year.

APA Q1 EPS $0.44 Misses $0.83 Estimate, Sales $1.38B Miss $2.20B Estimate

Armada Hoffler Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHH#NYSE">AHH</a>) affirms FY2025 FFO guidance from $1.00-$1.10 to $1.00-$1.10 vs $1.06 analyst estimate..

Armada Hoffler Properties Affirms FY2025 FFO Guidance of $1.00-$1.10 vs $1.06 Est

Based on our first quarter 2025 results and our outlook for the remainder of the year, we are reaffirming 2025 full year guidance for all financial measures.
<ul>
<li>Total Revenue of $925 million to $935 million</li>
<li>Adjusted EBITDA of $410 million to $420 million</li>
<li>Adjusted EPS of $1.30 to $1.35</li>
<li>Free Cash Flow of $175 million to $185 million</li>
</ul>

VRRM

Verra Mobility Affirms FY2025 Adj EPS Guidance of $1.30-$1.35 vs $1.32 Est; Affirms FY2025 Sales Guidance of $925.00M-$935.00M vs $931.57M Est

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) Q2 expected to be below $0.02 vs $0.01 Est. sees Q2 sales of $33.800 million-$34.400 million vs $35.17 million analyst estimate.

ONTF

ON24 Q2  expected to be below $0.02 vs $0.01 Est; Sees Q2 Sales $33.800M-$34.400M vs $35.17M Est

AXON

Axon Enterprise shares are trading higher after the company reported better-than-expected Q1 financial results and raised FY25 sales guidance.

Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) is looking for Q2 Adj EPS of $(0.10)-$(0.03) vs $0.04 analyst estimate. sees sales of $12.000 million-$16.000 million vs $17.20 million analyst estimate.

Silvaco Group Sees Q2 Adj EPS $(0.10)-$(0.03) vs $0.04 Est; Sees Sales $12.000M-$16.000M vs $17.20M Est

Armada Hoffler Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHH#NYSE">AHH</a>) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.26 by 3.85 percent. This is a 24.24 percent decrease over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $63.80 million which beat the analyst consensus estimate of $63.18 million by 0.98 percent. This is a 3.10 percent increase over sales of $61.88 million the same period last year.

Armada Hoffler Properties Q1 FFO $0.25 Misses $0.26 Estimate, Sales $63.80M Beat $63.18M Estimate

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) affirms FY2025 Adj EPS guidance from $0.02-$0.05 to $0.02-$0.05 vs $0.03 analyst estimate. Lowers FY2025 sales outlook from $138.60 million-$141.60 million to $133.70 million-$136.70 million vs $139.82 million estimate.

ON24 Affirms FY2025 Adj EPS Guidance of $0.02-$0.05 vs $0.03 Est; Lowers FY2025 Sales Guidance from $138.60M-$141.60M to $133.70M-$136.70M vs $139.82M Est

Crane NXT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXT#NYSE">CXT</a>) affirms FY2025 Adj EPS guidance from $4.00-$4.30 to $4.00-$4.30 vs $4.13 analyst estimate..

Crane NXT Affirms FY2025 Adj EPS Guidance of $4.00-$4.30 vs $4.13 Est; Sales Growth Of 6% To 8%

Health Care

Press Releases

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Power Nickel's (TSX.V: PNPN) Hole Delivers "BIG"- Gold Terra (TSX.V: YGT) Developments and Exploration Progress Reported – More Stocks Inside!

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

KTTA

KTTAW

OGEN

PNPNF

TSXV:PNPN

TSXV:YGT

YGTFF

Alzamend Neuro

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Azitra

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Oragenics

Palisade Bio

Palatin Techs

Sunshine Biopharma

SILO Pharma

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

VivoSim Labs

Longevity Health Holdings, Inc. - Common Stock

Comments

Pasithea Therapeutics

ニュース

最新ニュース Pasithea Therapeutics (NASDAQ:KTTA) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル